Visual Stimuli Plus Maze Test/Apparatus for the Detection of Visual Abnormalities in Rodent Models of Alzheimer's Disease

Tech ID: kor000977




Currently, there are no effective treatments or feasible screening tools for early detection and monitoring progression of Alzheimer’s disease (AD).

Current evidence indicates that amyloid-related changes likely occur 10-20 years prior to symptom manifestations, suggesting that they may be excellent biomarkers for prodromal AD if adequate detection methods can be implemented.

Noninvasive detection of the pathological hallmark, amyloid-ß protein (Aß) plaques, is limited in the brain. However, patients with AD also develop Aß plaques in the retina, possibly at presymptomatic stages. Accordingly, the Aß plaques in the retina may provide a superior alternative target for early testing.


Technology Description


To that end, the inventors investigated the development of the Aβ plaques and discovered that they often occur in distinct geographical regions in the AD retina. Therefore, the inventors determined that a visual test that detects visual dysfunction associated with the areas of the retina affected in AD may reliably screen for AD.

The present invention discloses a highly sensitive visual test maze to detect mild and specific changes in the vision of rodent models of AD. These changes could be then associated with the appearance of amyloid-beta plaques in the retina and can provide an earlier indication of functional impairment prior to manifestation of cognitive decline.

The rodent behavioral test evaluates visual dysfunctions associated with the retinal changes in AD models in relation to visual field, contrast and color distinction, and other ‘non-typical’ peripheral and night vision functions.

This early screening tool could be also implemented in humans.


Stage of Development


The Visual Plus Maze Device has been prototyped and tested with Wild Type and Transgenic AD Model Mice.




A number of visual tests exist for rodent models, however, all of them test visual acuity and other visual dysfunctions related to retinal areas that are not typically affected in AD. Contrary to the present technology, existing visual tests for rodent models would detect any visual — functional changes in AD transgenic models, and would not be limited to the visual abnormalities caused by AD. As such, existing tests would capture many false positives and would not provide a reliable screening model.




Early diagnostic of AD


Intellectual Property


•       PCT application PCT/US2017/035835 filed;

Patent Information:
For Information, Contact:
Julien Brohan
Maya Koronyo
Yosef Koronyo
Keith Black